The Ministry of Health reported that there is no risk of running out of the newest HIV medicine adopted by the government.
Like Gay Guide on Instagram
The speech was necessary because in recent months HIV-positive people in São Paulo, Minas Gerais, Rio de Janeiro and the Federal District have received single tablets of dolutegravir with lamivudine for just one month, instead of three months, as is customary.
The situation raised fears among many patients that there would be a shortage of the medicine, however, no user should worry, says the ministry.
In an interview with CBN radio, the director of the HIV/AIDS Department of the Ministry of Health, Draurio Barreira, stated that there will be no interruption in anyone’s treatment and that the change in distribution is made to help the introduction phase of the substance into the Unified System of health.
The promise is that quarterly delivery will resume in May.
Co-dosing dolutegravir with lamivudine is one of the newest advances in HIV treatment. Commercially called Dovato, the medicine replaces the consumption of two substances separately.
Anvisa approved the new drug in 2021. The government began distributing it at the end of 2023 only to those over 50 years of age.
The current phase is precisely the one in which more people with HIV will be able to switch from their current medications to Dovato.
